| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 146, 695-705, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
CV Clevenger, WP Chang, W Ngo, TL Pasha, KT Montone and JE Tomaszewski
Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia 19104.
The neuroendocrine hormone prolactin is a growth factor required for the proliferation and terminal differentiation of the human breast. These effects are mediated by the prolactin receptor, a member of the growth factor receptor family. Three prolactin receptor isoforms (long, intermediate, and short) have been identified in the rat, which differ in the length of their intracytoplasmic domains. In humans, however, only the long prolactin receptor isoform had been identified previously. The expression of the human intermediate prolactin receptor is demonstrated and preliminary evidence for a human short isoform is presented. Heterogeneous expression of prolactin receptor, at the immunoblot and immunohistochemical levels was observed in breast carcinoma specimens. A statistically significant correlation between prolactin receptor and estrogen receptor expression was noted. An autocrine/paracrine role for prolactin within breast tissues was further examined by performing reverse transcription polymerase chain reaction on RNA isolated from cell lines and clinical specimens with prolactin-specific primers. A 585-bp product was observed and found to be identical to human prolactin. The synthesis of prolactin by breast epithelium was confirmed by in situ hybridization analysis of breast tissues and the detection of bio- and immunoreactive prolactin in breast cancer lines. These analyses indicate that the principal site for prolactin expression within the normal or malignant breast residues within the epithelium. These data indicate that prolactin may participate in an autocrine/paracrine stimulatory loop within breast tissues and suggest a role for this growth factor in the pathogenesis of breast cancer.
This article has been cited by other articles:
![]() |
M. Bifulco, A. M. Malfitano, S. Pisanti, and C. Laezza Endocannabinoids in endocrine and related tumours Endocr. Relat. Cancer, June 1, 2008; 15(2): 391 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Plotnikov, Y. Li, T. H. Tran, W. Tang, J. P. Palazzo, H. Rui, and S. Y. Fuchs Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3{beta} Impairs Degradation of Prolactin Receptor Cancer Res., March 1, 2008; 68(5): 1354 - 1361. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Holt Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists J Psychopharmacol, March 1, 2008; 22(2_suppl): 28 - 37. [Abstract] [PDF] |
||||
![]() |
X. Ren, X. Zhang, A. S. Kim, A. M. Mikheev, M. Fang, R. C. Sullivan, R. E. Bumgarner, and H. Zarbl Comparative genomics of susceptibility to mammary carcinogenesis among inbred rat strains: role of reduced prolactin signaling in resistance of the Copenhagen strain Carcinogenesis, January 1, 2008; 29(1): 177 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sakamoto, B. A. Creamer, A. A. Triplett, and K.-U. Wagner The Janus Kinase 2 Is Required for Expression and Nuclear Accumulation of Cyclin D1 in Proliferating Mammary Epithelial Cells Mol. Endocrinol., August 1, 2007; 21(8): 1877 - 1892. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Polgar, B. Fogelgren, J. M. Shipley, and K. Csiszar Lysyl Oxidase Interacts with Hormone Placental Lactogen and Synergistically Promotes Breast Epithelial Cell Proliferation and Migration J. Biol. Chem., February 2, 2007; 282(5): 3262 - 3272. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Gadd and C. V. Clevenger Ligand-Independent Dimerization of the Human Prolactin Receptor Isoforms: Functional Implications Mol. Endocrinol., November 1, 2006; 20(11): 2734 - 2746. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Manhes, C. Kayser, P. Bertheau, B. Kelder, J. J Kopchick, P. A Kelly, P. Touraine, and V. Goffin Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J. Endocrinol., August 1, 2006; 190(2): 271 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Faupel-Badger, S. A. Prindiville, D. Venzon, B. K. Vonderhaar, J. A. Zujewski, and J. Eng-Wong Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1153 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Tworoger, P. Sluss, and S. E. Hankinson Association between Plasma Prolactin Concentrations and Risk of Breast Cancer among Predominately Premenopausal Women Cancer Res., February 15, 2006; 66(4): 2476 - 2482. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Nouhi, N. Chughtai, S. Hartley, E. Cocolakis, J.-J. Lebrun, and S. Ali Defining the Role of Prolactin as an Invasion Suppressor Hormone in Breast Cancer Cells Cancer Res., February 1, 2006; 66(3): 1824 - 1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Gil-Puig, S Seoane, M Blanco, M Macia, T Garcia-Caballero, C Segura, and R Perez-Fernandez Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation Eur. J. Endocrinol., August 1, 2005; 153(2): 335 - 344. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Miller, J. E. DeMaria, D. O. Freier, A. M. Riegel, and C. V. Clevenger Novel Association of Vav2 and Nek3 Modulates Signaling through the Human Prolactin Receptor Mol. Endocrinol., April 1, 2005; 19(4): 939 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Clevenger Roles and Regulation of Stat Family Transcription Factors in Human Breast Cancer Am. J. Pathol., November 1, 2004; 165(5): 1449 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Waters and B. L. Conway-Campbell The oncogenic potential of autocrine human growth hormone in breast cancer PNAS, October 19, 2004; 101(42): 14992 - 14993. [Full Text] [PDF] |
||||
![]() |
S. S. Tworoger, A. H. Eliassen, B. Rosner, P. Sluss, and S. E. Hankinson Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer Cancer Res., September 15, 2004; 64(18): 6814 - 6819. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Karp, H. Pan, M. Zhang, D. J. Buckley, L. A. Schuler, and A. R. Buckley Identification of HRPAP20: A Novel Phosphoprotein that Enhances Growth and Survival in Hormone-Responsive Tumor Cells Cancer Res., February 1, 2004; 64(3): 1016 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Acosta, R. M. Munoz, L. Gonzalez, A. Subtil-Rodriguez, M. A. Dominguez-Caceres, J. M. Garcia-Martinez, A. Calcabrini, I. Lazaro-Trueba, and J. Martin-Perez Src Mediates Prolactin-Dependent Proliferation of T47D and MCF7 Cells via the Activation of Focal Adhesion Kinase/Erk1/2 and Phosphatidylinositol 3-Kinase Pathways Mol. Endocrinol., November 1, 2003; 17(11): 2268 - 2282. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bernichtein, C. Kayser, K. Dillner, S. Moulin, J. J. Kopchick, J. A. Martial, G. Norstedt, O. Isaksson, P. A. Kelly, and V. Goffin Development of Pure Prolactin Receptor Antagonists J. Biol. Chem., September 19, 2003; 278(38): 35988 - 35999. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Beck, N. Y. Chen, K. J. Franek, and W. Y. Chen Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer Cancer Res., July 1, 2003; 63(13): 3598 - 3604. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kindblom, K. Dillner, L. Sahlin, F. Robertson, C. Ormandy, J. Tornell, and H. Wennbo Prostate Hyperplasia in a Transgenic Mouse with Prostate-Specific Expression of Prolactin Endocrinology, June 1, 2003; 144(6): 2269 - 2278. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Brockman, M. D. Schroeder, and L. A. Schuler PRL Activates the Cyclin D1 Promoter Via the Jak2/Stat Pathway Mol. Endocrinol., April 1, 2002; 16(4): 774 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhang, W. Li, L. Holle, N. Chen, and W. Y. Chen A Novel Design of Targeted Endocrine and Cytokine Therapy for Breast Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1196 - 1205. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Schroeder, J. Symowicz, and L. A. Schuler PRL Modulates Cell Cycle Regulators in Mammary Tumor Epithelial Cells Mol. Endocrinol., January 1, 2002; 16(1): 45 - 57. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-Y. Yu-Lee Prolactin Modulation of Immune and Inflammatory Responses Recent Prog. Horm. Res., January 1, 2002; 57(1): 435 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Park, H. Lee, C. Riedel, J. Hulit, P. E. Scherer, R. G. Pestell, and M. P. Lisanti Prolactin Negatively Regulates Caveolin-1 Gene Expression in the Mammary Gland during Lactation, via a Ras-dependent Mechanism J. Biol. Chem., December 14, 2001; 276(51): 48389 - 48397. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Gill, D Peston, B K Vonderhaar, and S Shousha Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study J. Clin. Pathol., December 1, 2001; 54(12): 956 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-y. Yu-Lee Stimulation of interferon regulatory factor-1 by prolactin Lupus, October 1, 2001; 10(10): 691 - 699. [Abstract] [PDF] |
||||
![]() |
M. Gebre-Medhin, L.-G. Kindblom, H. Wennbo, J. Tornell, and J. M. Meis-Kindblom Growth Hormone Receptor Is Expressed in Human Breast Cancer Am. J. Pathol., April 1, 2001; 158(4): 1217 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Tseng, D. Vicent, J. Zhu, Y. Niu, A. Adeyinka, J. S. Moyers, P. H. Watson, and C. R. Kahn Regulation of Growth and Tumorigenicity of Breast Cancer Cells by the Low Molecular Weight GTPase Rad and Nm23 Cancer Res., March 1, 2001; 61(5): 2071 - 2079. [Abstract] [Full Text] |
||||
![]() |
I. Olazabal, J. Muñoz, S. Ogueta, E. Obregón, and J. P. García-Ruiz Prolactin (PRL)-PRL Receptor System Increases Cell Proliferation Involving JNK (c-Jun Amino Terminal Kinase) and AP-1 Activation: Inhibition by Glucocorticoids Mol. Endocrinol., April 1, 2000; 14(4): 564 - 575. [Abstract] [Full Text] |
||||
![]() |
D. Melck, L. De Petrocellis, P. Orlando, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation Endocrinology, January 1, 2000; 141(1): 118 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Ahonen, P. L. Härkönen, J. Laine, H. Rui, P. M. Martikainen, and M. T. Nevalainen Prolactin Is a Survival Factor for Androgen-Deprived Rat Dorsal and Lateral Prostate Epithelium in Organ Culture Endocrinology, November 1, 1999; 140(11): 5412 - 5421. [Abstract] [Full Text] |
||||
![]() |
W. Y. Chen, P. Ramamoorthy, N.-y. Chen, R. Sticca, and T. E. Wagner A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis Clin. Cancer Res., November 1, 1999; 5(11): 3583 - 3593. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. CHIKANZA Prolactin and Neuroimmunomodulation: In Vitro and in Vivo Observations Ann. N.Y. Acad. Sci., June 22, 1999; 876(1): 119 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Hankinson, W. C. Willett, D. S. Michaud, J. E. Manson, G. A. Colditz, C. Longcope, B. Rosner, and F. E. Speizer Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, April 7, 1999; 91(7): 629 - 634. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Leav, F. B. Merk, K. F. Lee, M. Loda, M. Mandoki, J. E. McNeal, and S.-m. Ho Prolactin Receptor Expression in the Developing Human Prostate and in Hyperplastic, Dysplastic, and Neoplastic Lesions Am. J. Pathol., March 1, 1999; 154(3): 863 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. De Petrocellis, D. Melck, A. Palmisano, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation PNAS, July 7, 1998; 95(14): 8375 - 8380. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Touraine, J.-F. Martini, B. Zafrani, J.-C. Durand, F. Labaille, C. Malet, A. Nicolas, C. Trivin, M.-C. Postel-Vinay, F. Kuttenn, et al. Increased Expression of Prolactin Receptor Gene Assessed by Quantitative Polymerase Chain Reaction in Human Breast Tumors Versus Normal Breast Tissues J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 667 - 674. [Abstract] [Full Text] |
||||
![]() |
T.-J. Chen, C. B. Kuo, K. F. Tsai, J.-W. Liu, D.-Y. Chen, and A. M. Walker Development of Recombinant Human Prolactin Receptor Antagonists by Molecular Mimicry of the Phosphorylated Hormone Endocrinology, February 1, 1998; 139(2): 609 - 616. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Reynolds, K. T. Montone, C. M. Powell, J. E. Tomaszewski, and C. V. Clevenger Expression of Prolactin and Its Receptor in Human Breast Carcinoma Endocrinology, December 1, 1997; 138(12): 5555 - 5560. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jinno, Y. Katsumata, T. Hoshiai, Y. Nakamura, K. Matsumoto, and Y. Yoshimura A Therapeutic Role of Prolactin Supplementation in Ovarian Stimulation for in Vitro Fertilization: The Bromocriptine-Rebound Method J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3603 - 3611. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Ormandy, R. E. Hall, D. L. Manning, J. F. R. Robertson, R. W. Blamey, P. A. Kelly, R. I. Nicholson, and R. L. Sutherland Coexpression and Cross-Regulation of the Prolactin Receptor and Sex Steroid Hormone Receptors in Breast Cancer J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3692 - 3699. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Schuler, R. J. Nagel, J. Gao, N. D. Horseman, and M. A. Kessler Prolactin Receptor Heterogeneity in Bovine Fetal and Maternal Tissues Endocrinology, August 1, 1997; 138(8): 3187 - 3194. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jin, X. Qian, E. Kulig, B. W. Scheithauer, R. Calle-Rodrigue, C. Abboud, D. H. Davis, K. Kovacs, and R. V. Lloyd Prolactin Receptor Messenger Ribonucleic Acid in Normal and Neoplastic Human Pituitary Tissues J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 963 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
C J Ormandy, A Camus, J Barra, D Damotte, B Lucas, H Buteau, M Edery, N Brousse, C Babinet, N Binart, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes & Dev., January 15, 1997; 11(2): 167 - 178. [Abstract] [PDF] |
||||
![]() |
T. Yamauchi, N. Yamauchi, K. Ueki, T. Sugiyama, H. Waki, H. Miki, K. Tobe, S. Matsuda, T. Tsushima, T. Yamamoto, et al. Constitutive Tyrosine Phosphorylation of ErbB-2 via Jak2 by Autocrine Secretion of Prolactin in Human Breast Cancer J. Biol. Chem., October 20, 2000; 275(43): 33937 - 33944. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Gaemers, H. L. Vos, H. H. Volders, S. W. van der Valk, and J. Hilkens A STAT-responsive Element in the Promoter of the Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma Cells J. Biol. Chem., February 23, 2001; 276(9): 6191 - 6199. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |